Yetong Liu

Yetong Liu

Auto-generated profile, based on publicly available information

Yetong Liu

Department of Epidemiology and Health Statistics, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2025 in Journal of Global Health
Verified
Journal Article
Open access
YLYetong Liu
Yetong Liu
WBWenming Bian
Wenming Bian
SLSidong Li
Sidong Li
ZLZhe Lv
Zhe Lv
YLYizhen Lyu
Yizhen Lyu
CLChao Li
Chao Li
Cardiovascular disease (CVD) is the leading cause of death and disability worldwide [1,2]. Given this global impact, models that estimate individual CVD risk are highly important for clinical decision-making, as well as informing targeted prevention efforts and primary prevention initiatives [3–5]. Many such models have been developed and applied in practice, with the Framingham, SCORE2, […]

1 June 2026 in Hypertension
Verified
Journal Article
Closed access
YLYizhen Lv
Yizhen Lv
WBWenming Bian
Wenming Bian
YLYezhou Liu
Yezhou Liu
YLYetong Liu
Yetong Liu
JZJiaheng Zhang
Jiaheng Zhang
CLChao Li
Chao Li
BACKGROUND: Contemporary hypertension guidelines emphasize individualized blood pressure (BP) management, often incorporating age; yet chronological age alone may be insufficient to guide optimal treatment. The frailty index offers a multidimensional measure of biological aging and may better guide BP management. METHODS: We pooled participant-level data from SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes). The frailty index was calculated using a 31-item Rockwood cumulative-deficit model, with frailty defined as a frailty index >0.21. Participants were also categorized by age (<65 versus ≥65 years). Systolic BP (SBP) time in target range (TTR) was calculated using linear interpolation across 10 mm Hg intervals. Restricted cubic splines and stratified Cox models were used to assess the association between TTR within predefined SBP targets and major adverse cardiovascular events. RESULTS: A total of 19 230 participants were included in the analysis (mean age, 65.2 years; 49.0% women; 68.2% classified as frail). Restricted cubic spline analyses showed a J-shaped relationship between average SBP and major adverse cardiovascular events, with clearer separation by frailty than by age. Among frail individuals, greater time spent within SBP intervals between 110 and 140 mm Hg was associated with lower major adverse cardiovascular event risk (hazard ratios per 10% increase in TTR, 0.92–0.94), whereas among nonfrail individuals, greater time spent below 130 mm Hg was associated with lower risk (hazard ratios per 10% increase in TTR, 0.89–0.98). Age demonstrated limited discrimination. Findings were consistent in separate analyses of SPRINT and ACCORD. CONCLUSIONS: The frailty index, rather than chronological age, more accurately discriminates optimal SBP targets in hypertensive patients, whereas chronological age may remain a more practical tool in resource-limited settings.

18 June 2025 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
JZJiaheng Zhang
Jiaheng Zhang
HXHaibao Xu
Haibao Xu
YLYezhou Liu
Yezhou Liu
YLYizhen Lv
Yizhen Lv
WBWenming Bian
Wenming Bian
CLChao Li
Chao Li
Through the utilization of the time in target range (TTR), our study aims to reassess the differential risks of cardiorenal diseases associated with inconsistent pre-diabetes criteria, as defined by the World Health Organization (WHO) and the American Diabetes Association (ADA). We performed a pooled analysis from the Atherosclerosis Risk in Communities study and the Multi-Ethnic Study of Atherosclerosis study. TTR for each patient was calculated using linear interpolation before the outcome. Cox regression models were used to assess the association of FPG TTR with the clinical outcomes. A total of 14 346 patients were included. Using adjusted Cox regression model, both ADA (HR: 1.17, 95 % CI: 1.09 to 1.25) and WHO (HR: 1.37, 95 % CI: 1.21 to 1.57) defined pre-diabetes range were associated with an increased risk of major adverse cardiovascular events (MACE). Additionally, individuals with FPG levels in the range between the two standards (100-110 mg/dL) also had a higher risk of MACE (HR: 1.24, 95 % CI: 1.09 to 1.40). Meanwhile, no significant relation was found between FPG threshold and Chronic kidney disease (CKD). The threshold defined by the ADA guidelines serves to protect cardiovascular health across a broader population while not increasing the risk of CKD.